Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Zydus Cadila Reels Under Double FDA Warning

This article was originally published in Scrip

Executive Summary

Shares of Cadila Healthcare were pounded on Indian bourses on New Year's eve after the FDA issued warning letters against two of the firm's sites, though the company's top brass stressed that de-risking efforts, by way of site transfers for critical products, were underway.

Advertisement
Advertisement
UsernamePublicRestriction

Register